Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 7, 2008, Pages 2652-2657

  Zhao, Li ^a   Vogt, Peter K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

AKT; Cancer; Molecular mechanisms; p85; RAS

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P85; PROTEIN SUBUNIT; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; GENE MUTATION; GENETIC ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL CULTURE; CHICKEN; GENETICS; METABOLISM; MUTATION; PHENOTYPE; PROTEIN MOTIF; TRANSGENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID MOTIFS; ANIMALS; CELLS, CULTURED; CHICKENS; MUTATION; PHENOTYPE; PROTEIN BINDING; TRANSGENES;

EID: 40649096375     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712169105     Document Type: Article

References (42)

1. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5:921-929.
2. Bachman KE, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775.
3. Broderick DK, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64:5048-5050.
4. Campbell IG, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681.
5. Hartmann C, et al. (2005) PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 109:639-642.
6. Lee JW, et al. (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477-1480.
7. Levine DA, et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11:2875-2878.
8. Li VS, et al. (2005) Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5:29.
9. Saal LH, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559.
10. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
11. Wang Y, et al. (2005) PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 25:322.
12. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
13. Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253:239-254.
14. Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3:317-330.
15. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 24:366-376.
16. Deane JA, Fruman DA (2004) Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol 22:563-598.
17. Walker EH, et al. (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402:313-320.
18. Yu J, et al. (1998) Regulation of the p85/p110 phosphatidylinositol 3′-kinase: Stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18:1379-1387.
19. Skolnik EY, et al. (1991) Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65:83-90.
20. Rodriguez-Viciana P, et al. (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532.
21. Rodriguez-Viciana P, et al. (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442-2451.
22. Chan TO, et al. (2002) Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1:181-191.
23. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77-82.
24. Kang S, Bader AG, Zhao L, Vogt PK (2005) Mutated PI3-kinases: Cancer targets on a silver platter. Cell Cycle 4:578-581.
25. Ikenoue T, et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562-4567.
26. Isakoff SJ, et al. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992-11000.
27. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802-807.
28. Zhao JJ, et al. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102:18443-18448.
29. Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103:1475-1479.
30. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104:5569-5574.
31. Corvera S, Czech MP (1998) Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 8:442-446.
32. Shekar SC, et al. (2005) Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280:27850-27855.
33. Miled N, et al. (2007) Mechanism of two classes of cancer mutations in the phospho-inositide 3-kinase catalytic subunit. Science 317:239-242.
34. Huang CH, et al. (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318:1744-1748.
35. Carson JD, et al. (2008) Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphatidylinositol 3-kinase. Biochem J 409:519-524.
36. Pacold ME, et al. (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103:931-943.
37. Gupta S, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957-968.
38. Nimnual AS, Yatsula BA, Bar-Sagi D (1998) Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279:560-563.
39. Aoki M, et al. (2000) The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity. J Biol Chem 275:6267-6275.
40. Aoki M, et al. (1998) The akt kinase: Molecular determinants of oncogenicity. Proc Natl Acad Sci USA 95:14950-14955.
41. Vogt PK (1969) in Fundamental Techniques in Virology, eds Habel K, Salzman NP (Academic, New York), pp 198-211.
42. Kawai S, Nishizawa M (1984) New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol 4:1172-1174.